Alivus Life Sciences Limited (BOM: 543322)

Market Cap	135.36B
Revenue (ttm)	22.05B
Net Income (ttm)	4.24B
Shares Out	n/a
EPS (ttm)	34.46
PE Ratio	31.96
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,050
Average Volume	5,071
Open	1,035.05
Previous Close	1,085.80
Day's Range	1,035.05 - 1,110.00
52-Week Range	666.05 - 1,335.00
Beta	n/a
RSI	63.39
Earnings Date	Jan 23, 2025

About Alivus Life Sciences

Alivus Life Sciences Limited engages in the development, manufacture, and marketing of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers various APIs, such as olmesartan, telmisartan, perindopril, atovaquone, solifenacin, mirabegron, sitagliptin, zonisamide, adapalene, and rosuvastatin. It also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. The company’s APIs are used in various therapeutic segments, in...

• Industry: Medicinal Chemicals and Botanical Products
• Founded: 2011
• Employees: 2,014
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543322

Financial Performance

In 2023, Alivus Life Sciences's revenue was 22.83 billion, an increase of 5.64% compared to the previous year's 21.61 billion. Earnings were 4.71 billion, an increase of 0.84%.